FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154348413> ?p ?o ?g. }

• W2154348413 abstract "Diabetes, and particularly type 2 diabetes, is becoming a global epidemic. Approximately 180 million people are affected worldwide and as many as 300 millions are expected to be affected in 2025 [1]. Dietary errors, little physical activity, obesity and the metabolic syndrome are the main causes of this epidemic. In men with type 2 diabetes the risk of cardiovascular disease is increased 2 to 3 times [2]. Diabetes has a disproportionate impact on woman health, with a risk of cardiovascular events that is much higher than that of men (a 5to 7-fold absolute increase) [3]. Even though macrovascular disease is due to the early occurrence of atherosclerosis with great severity and diffuse distribution, the ultimate mechanism in the development of cardiovascular events (myocardial infarction, ischemic stroke and peripheral arterial disease) is the formation of occlusive thrombi on vulnerable atherosclerotic plaques. Accordingly, antithrombotic drugs have been widely employed for primary prevention in at-risk people with type 2 diabetes. Among these drugs, antiplatelet agents are those most frequently used, whereas there is a paucity of data on other drugs such as vitamin-K antagonists and heparins. In 1998 the American Diabetes Association (ADA) recommended, in people with diabetes older than 40who had one ormore cardiovascular risk factor, primary prophylaxis with aspirin, i.e., the oldest, cheapest and most widely used antiplatelet agent [4]. This recommendation was jointly reiterated in 2007 by ADA and the American Heart Association (AHA), that identified as additional risk factors prompting primary prevention with aspirin a family history of cardiovascular events, hypertension, smoking, dyslipidemia and microalbuminuria [5]. Pertaining to aspirin dosages, ADA and AHA recommended 75 to 162 mg/day [5]. Unfortunately, there is more and more evidence that, in spite of the forementioned recommendations of ADA and AHA, the efficacy of aspirin in the primary prevention of cardiovascular events in type 2 diabetes is much smaller than that exerted in non-diabetic people. The guidelines recommending aspirin for primary prevention in diabetes were primarily extrapolated from the results obtained in the frame of trials carried out in people enrolled for being at high risk of cardiovascular disease, with very few studies exclusively and purposely carried out in diabetics. The first evidence of the limited efficacy of antiplatelet therapy with aspirin in the frame of primary prevention stems for the 2002 meta-analysis of the Antithrombotic Trialists' Collaboration (287 trials, 135.000 participants) [6]. The relative reduction of major cardiovascular events in the subgroup of diabetics (5126 participants) was only 7%, much less than that observed in other asymptomatic people at risk of cardiovascular events (22%). Another caveat on the limited efficacy of aspirin in diabetes was subsequently provided by the Primary Prevention Project, carried out in 4500 people aged 50 or more who had no overt cardiovascular disease but at least one risk factor [7]. According" @default.
• W2154348413 created "2016-06-24" @default.
• W2154348413 creator A5065489740 @default.
• W2154348413 date "2010-06-01" @default.
• W2154348413 modified "2023-09-23" @default.
• W2154348413 title "Aspirin as antiplatelet agent in diabetes: Cons" @default.
• W2154348413 cites W1991655882 @default.
• W2154348413 cites W1992794479 @default.
• W2154348413 cites W2023365160 @default.
• W2154348413 cites W2024352468 @default.
• W2154348413 cites W2031484324 @default.
• W2154348413 cites W2034942998 @default.
• W2154348413 cites W2046790845 @default.
• W2154348413 cites W2050820265 @default.
• W2154348413 cites W2075388377 @default.
• W2154348413 cites W2086623284 @default.
• W2154348413 cites W2086863177 @default.
• W2154348413 cites W2089866062 @default.
• W2154348413 cites W2100089051 @default.
• W2154348413 cites W2100209149 @default.
• W2154348413 cites W2100500261 @default.
• W2154348413 cites W2102397849 @default.
• W2154348413 cites W2105881737 @default.
• W2154348413 cites W2138058610 @default.
• W2154348413 cites W2138597449 @default.
• W2154348413 cites W2156538498 @default.
• W2154348413 cites W2172488527 @default.
• W2154348413 cites W2404343508 @default.
• W2154348413 cites W2529190803 @default.
• W2154348413 cites W311320695 @default.
• W2154348413 doi "https://doi.org/10.1016/j.ejim.2010.03.009" @default.
• W2154348413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20493413" @default.
• W2154348413 hasPublicationYear "2010" @default.
• W2154348413 type Work @default.
• W2154348413 sameAs 2154348413 @default.
• W2154348413 citedByCount "1" @default.
• W2154348413 crossrefType "journal-article" @default.
• W2154348413 hasAuthorship W2154348413A5065489740 @default.
• W2154348413 hasConcept C126322002 @default.
• W2154348413 hasConcept C127413603 @default.
• W2154348413 hasConcept C134018914 @default.
• W2154348413 hasConcept C164705383 @default.
• W2154348413 hasConcept C2777015399 @default.
• W2154348413 hasConcept C2777180221 @default.
• W2154348413 hasConcept C2777628954 @default.
• W2154348413 hasConcept C2779134260 @default.
• W2154348413 hasConcept C2780645631 @default.
• W2154348413 hasConcept C500558357 @default.
• W2154348413 hasConcept C50440223 @default.
• W2154348413 hasConcept C555293320 @default.
• W2154348413 hasConcept C71924100 @default.
• W2154348413 hasConcept C78519656 @default.
• W2154348413 hasConceptScore W2154348413C126322002 @default.
• W2154348413 hasConceptScore W2154348413C127413603 @default.
• W2154348413 hasConceptScore W2154348413C134018914 @default.
• W2154348413 hasConceptScore W2154348413C164705383 @default.
• W2154348413 hasConceptScore W2154348413C2777015399 @default.
• W2154348413 hasConceptScore W2154348413C2777180221 @default.
• W2154348413 hasConceptScore W2154348413C2777628954 @default.
• W2154348413 hasConceptScore W2154348413C2779134260 @default.
• W2154348413 hasConceptScore W2154348413C2780645631 @default.
• W2154348413 hasConceptScore W2154348413C500558357 @default.
• W2154348413 hasConceptScore W2154348413C50440223 @default.
• W2154348413 hasConceptScore W2154348413C555293320 @default.
• W2154348413 hasConceptScore W2154348413C71924100 @default.
• W2154348413 hasConceptScore W2154348413C78519656 @default.
• W2154348413 hasLocation W21543484131 @default.
• W2154348413 hasLocation W21543484132 @default.
• W2154348413 hasOpenAccess W2154348413 @default.
• W2154348413 hasPrimaryLocation W21543484131 @default.
• W2154348413 hasRelatedWork W1650296314 @default.
• W2154348413 hasRelatedWork W1973045375 @default.
• W2154348413 hasRelatedWork W1977740948 @default.
• W2154348413 hasRelatedWork W1988732202 @default.
• W2154348413 hasRelatedWork W1988773538 @default.
• W2154348413 hasRelatedWork W1998329864 @default.
• W2154348413 hasRelatedWork W2002023598 @default.
• W2154348413 hasRelatedWork W2011873643 @default.
• W2154348413 hasRelatedWork W2075268368 @default.
• W2154348413 hasRelatedWork W2092632167 @default.
• W2154348413 hasRelatedWork W2110112177 @default.
• W2154348413 hasRelatedWork W2148443271 @default.
• W2154348413 hasRelatedWork W2149745574 @default.
• W2154348413 hasRelatedWork W2531454911 @default.
• W2154348413 hasRelatedWork W2769666386 @default.
• W2154348413 hasRelatedWork W2943728788 @default.
• W2154348413 hasRelatedWork W2976695148 @default.
• W2154348413 hasRelatedWork W2998925776 @default.
• W2154348413 hasRelatedWork W3021103983 @default.
• W2154348413 hasRelatedWork W3134164723 @default.
• W2154348413 isParatext "false" @default.
• W2154348413 isRetracted "false" @default.
• W2154348413 magId "2154348413" @default.
• W2154348413 workType "article" @default.